{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:26:34Z","timestamp":1795011994175,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GO 2068\/1-1"],"award-info":[{"award-number":["GO 2068\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently, complete surgical resection represents the only potentially curative treatment option for Biliary Tract Cancer (BTC) including Gallbladder Cancer (GBC). Even after curative resection, 5-year OS is only 20\u201340%. Gallbladder carcinoma is relatively rare, but still the fifth most common neoplasm of the digestive tract and even the most frequent cancer of the biliary system. Gallbladder carcinoma is suspected preoperatively in only 30% of all pts., while the majority of cases are discovered incidentally by the pathologist after cholecystectomy for a benign indication. For improving curative rates in BTC and GBC, early systemic therapy combined with radical resection seems to be a promising approach. The earliest moment to apply chemotherapy would be in front of radical surgery. The encouraging results of neoadjuvant\/perioperative concepts in other malignancies provide an additional rationale to use this treatment in the early phase of GBC management and even ICC\/ECC. Especially because data regarding pure adjuvant chemotherapy in BTC\u2019s are conflicting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a multicenter, randomized, controlled, open-label phase III study including pts. with incidentally discovered GBCs after simple cholecystectomy in front of radical liver resection and pts. with resectable\/ borderline resectable cholangiocarcinomas (ICC\/ ECC) scheduled to receive perioperative chemotherapy (Gemcitabine + Cisplatin 3\u2009cycles pre- and post-surgery) or surgery alone followed by a therapy of investigator\u2019s choice. Primary endpoint is OS; secondary endpoints are PFS, R0-resection rate, toxicity, perioperative morbidity, mortality and QoL. A total of\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009333 patients with GBC or BTC will be included. Recruitment has started in August 2019.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The current proposed phase III GAIN study investigates whether induction chemotherapy followed by radical resection in ICC\/ECC and re-resection in IGBC (and \u2013 if possible \u2013 postoperative chemotherapy) prolongs overall survival compared to radical surgery alone for incidental gallbladder carcinoma and primary resectable or borderline resectable cholangiocarcinoma. Utilizing a neoadjuvant approach including a second radical surgery will help to raise awareness for the necessity of radical surgery, especially second radical completion surgery in IGBC and improve the adherence to the guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03673072\">NCT03673072<\/jats:ext-link>\n                      from 17.09.2018. EudraCT number: 2017\u2013004444-38 from 02.11.2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-6610-4","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T07:45:46Z","timestamp":1583739946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC\/ECC) \u2013 a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)\u2013 the AIO\/ CALGP\/ ACO- GAIN-trial \u2013"],"prefix":"10.1186","volume":"20","author":[{"given":"Thorsten O.","family":"Goetze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf O.","family":"Bechstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4432-5507","authenticated-orcid":false,"given":"Ulli Simone","family":"Bankstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven A.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pauligk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompiliu","family":"Piso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddin","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"issue":"7","key":"6610_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4251\/wjgo.v9.i7.268","volume":"9","author":"H Kayhanian","year":"2017","unstructured":"Kayhanian H, Smyth EC, Braconi C. Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointestinal Oncol. 2017;9(7):268\u201380.","journal-title":"World J Gastrointestinal Oncol"},{"issue":"16","key":"6610_CR2","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1517\/14656566.9.16.2843","volume":"9","author":"D Seehofer","year":"2008","unstructured":"Seehofer D, Kamphues C, Neuhaus P. Management of bile duct tumors. Expert Opin Pharmacother. 2008;9(16):2843\u201356.","journal-title":"Expert Opin Pharmacother"},{"issue":"41","key":"6610_CR3","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.3748\/wjg.14.6289","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Yan LN. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14(41):6289\u201397.","journal-title":"World J Gastroenterol"},{"issue":"42","key":"6610_CR4","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.3748\/wjg.14.6458","volume":"14","author":"Y Ustundag","year":"2008","unstructured":"Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008;14(42):6458\u201366.","journal-title":"World J Gastroenterol"},{"issue":"9935","key":"6610_CR5","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London, England). 2014;383(9935):2168\u201379.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"6610_CR6","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893\u2013917.","journal-title":"Int J Cancer"},{"key":"6610_CR7","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"issue":"6","key":"6610_CR8","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268\u201389.","journal-title":"J Hepatol"},{"issue":"6","key":"6610_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7(6):593\u2013600.","journal-title":"Ann Oncol"},{"issue":"43","key":"6610_CR10","doi-asserted-by":"publisher","first-page":"12211","DOI":"10.3748\/wjg.v21.i43.12211","volume":"21","author":"Goetze TO","year":"2015","unstructured":"Goetze TO. Gallbladder carcinoma: prognostic factors and therapeutic options. World J Gastroenterol. 2015;21(43):12211\u20137.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"6610_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1055\/s-2003-38795","volume":"128","author":"V Paolucci","year":"2003","unstructured":"Paolucci V, Neckell M, Goetze TO. Unsuspected gallbladder carcinoma--the CAE-S\/CAMIC registry. Zentralbl Chir. 2003;128(4):309\u201312.","journal-title":"Zentralbl Chir"},{"issue":"2","key":"6610_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s00464-005-0121-x","volume":"20","author":"TO Goetze","year":"2006","unstructured":"Goetze TO, Paolucci V. Does laparoscopy worsen the prognosis for incidental gallbladder cancer? Surg Endosc. 2006;20(2):286\u201393.","journal-title":"Surg Endosc"},{"issue":"1","key":"6610_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/SLA.0b013e318154bf5d","volume":"247","author":"TO Goetze","year":"2008","unstructured":"Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg. 2008;247(1):104\u20138.","journal-title":"Ann Surg"},{"issue":"11","key":"6610_CR14","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1007\/s00464-008-9747-9","volume":"22","author":"TO Goetze","year":"2008","unstructured":"Goetze TO, Paolucci V. Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German registry. Surg Endosc. 2008;22(11):2462\u20135.","journal-title":"Surg Endosc"},{"issue":"10","key":"6610_CR15","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00268-009-0163-7","volume":"33","author":"TO Goetze","year":"2009","unstructured":"Goetze TO, Paolucci V. Use of retrieval bags in incidental gallbladder cancer cases. World J Surg. 2009;33(10):2161\u20135.","journal-title":"World J Surg"},{"issue":"9","key":"6610_CR16","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1007\/s00464-010-0914-4","volume":"24","author":"TO Goetze","year":"2010","unstructured":"Goetze TO, Paolucci V. Adequate extent in radical re-resection of incidental gallbladder carcinoma: analysis of the German registry. Surg Endosc. 2010;24(9):2156\u201364.","journal-title":"Surg Endosc"},{"issue":"Suppl 2","key":"6610_CR17","first-page":"e43","volume":"139","author":"TO Goetze","year":"2014","unstructured":"Goetze TO, Paolucci V. Immediate radical re-resection of incidental T1b gallbladder cancer and the problem of an adequate extent of resection (results of the German registry \"incidental gallbladder cancer\"). Zentralbl Chir. 2014;139(Suppl 2):e43\u20138.","journal-title":"Zentralbl Chir"},{"issue":"5","key":"6610_CR18","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00464-011-2044-z","volume":"26","author":"V Paolucci","year":"2012","unstructured":"Goetze TO, Paolucci V. The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German registry. Surg Endosc. 2012;26(5):1382\u20139.","journal-title":"Surg Endosc"},{"issue":"8","key":"6610_CR19","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00464-013-2819-5","volume":"27","author":"TO Goetze","year":"2013","unstructured":"Goetze TO, Paolucci V. Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique: analysis of 837 incidental gallbladder carcinomas in the German registry. Surg Endosc. 2013;27(8):2821\u20138.","journal-title":"Surg Endosc"},{"issue":"3","key":"6610_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/SLA.0b013e3182a1599b","volume":"258","author":"CN Gutt","year":"2013","unstructured":"Gutt CN, Encke J, Koninger J, Harnoss JC, Weigand K, Kipfmuller K, et al. Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). Ann Surg. 2013;258(3):385\u201393.","journal-title":"Ann Surg"},{"issue":"2","key":"6610_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00104-013-2587-8","volume":"85","author":"TO Goetze","year":"2014","unstructured":"Goetze TO, Paolucci V. Incidental T1b-T3 gallbladder carcinoma. Extended cholecystectomy as an underestimated prognostic factor-results of the German registry. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 2014;85(2):131\u20138.","journal-title":"Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen"},{"issue":"48","key":"6610_CR22","doi-asserted-by":"publisher","first-page":"18445","DOI":"10.3748\/wjg.v20.i48.18445","volume":"20","author":"TO Goetze","year":"2014","unstructured":"Goetze TO, Paolucci V. Influence of high- and low-volume liver surgery in gallbladder carcinoma. World J Gastroenterol. 2014;20(48):18445\u201351.","journal-title":"World J Gastroenterol"},{"key":"6610_CR23","doi-asserted-by":"crossref","unstructured":"Gutt C, Jenssen C, Barreiros A-P, Goetze TO, Stokes CS, Lynen-Jansen P, et al. Aktualisierte S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft f\u00fcr Allgemein- und Viszeralchirurgie (DGAV) zur Pr\u00e4vention, Diagnostik und Behandlung von GallensteinenAWMF Online; 2018.","DOI":"10.1055\/a-0644-2972"},{"key":"6610_CR24","unstructured":"Gutt C, Jenssen C, Barreiros A-P, Goetze TO, Stokes CS, Lynen-Jansen P, et al. Aktualisierte S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft f\u00fcr Allgemein-und Viszeralchirurgie (DGAV) zur Pr\u00e4vention, Diagnostik und Behandlung von Gallensteinen. Z Gastroenterol. 2000;38:449\u201368."},{"issue":"7","key":"6610_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00268-004-7289-4","volume":"28","author":"I Endo","year":"2004","unstructured":"Endo I, Shimada H, Takimoto A, Fujii Y, Miura Y, Sugita M, et al. Microscopic liver metastasis: prognostic factor for patients with pT2 gallbladder carcinoma. World J Surg. 2004;28(7):692\u20136.","journal-title":"World J Surg"},{"issue":"5","key":"6610_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/00000658-199611000-00008","volume":"224","author":"DL Bartlett","year":"1996","unstructured":"Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 1996;224(5):639\u201346.","journal-title":"Ann Surg"},{"issue":"14","key":"6610_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"30","key":"6610_CR28","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28(30):4581\u20136.","journal-title":"J Clin Oncol"},{"issue":"7","key":"6610_CR29","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s11605-010-1203-1","volume":"14","author":"A Saxena","year":"2010","unstructured":"Saxena A, Chua TC, Sarkar A, Chu F, Morris DL. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointestinal Surg. 2010;14(7):1128\u201338.","journal-title":"J Gastrointestinal Surg"},{"issue":"10","key":"6610_CR30","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1245\/s10434-008-0081-1","volume":"15","author":"D Tamandl","year":"2008","unstructured":"Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15(10):2787\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6610_CR31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-009-9970-0","volume":"33","author":"A Guglielmi","year":"2009","unstructured":"Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg. 2009;33(6):1247\u201354.","journal-title":"World J Surg"},{"issue":"1","key":"6610_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13304-010-0007-x","volume":"62","author":"G Nuzzo","year":"2010","unstructured":"Nuzzo G, Giuliante F, Ardito F, De Rose AM, Vellone M, Clemente G, et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg. 2010;62(1):11\u20139.","journal-title":"Updates Surg"},{"issue":"3","key":"6610_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1245\/s10434-010-1325-4","volume":"18","author":"Y Murakami","year":"2011","unstructured":"Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18(3):651\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"6610_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ctrv.2008.11.009","volume":"35","author":"C Anderson","year":"2009","unstructured":"Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009;35(4):322\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"6610_CR35","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-009-0631-1","volume":"16","author":"SB Choi","year":"2009","unstructured":"Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16(11):3048\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"6610_CR36","first-page":"2286","volume":"122","author":"SQ Li","year":"2009","unstructured":"Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD, et al. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma. Chin Med J (Engl). 2009;122(19):2286\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"6610_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1055\/s-2007-963437","volume":"45","author":"F Lammert","year":"2007","unstructured":"Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmuller F, et al. S3-guidelines for diagnosis and treatment of gallstones. German Society for Digestive and Metabolic Diseases and German Society for Surgery of the Alimentary Tract. Z Gastroenterol. 2007;45(9):971\u20131001.","journal-title":"Z Gastroenterol"},{"issue":"6","key":"6610_CR38","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/1097-0142(19920915)70:6<1498::AID-CNCR2820700609>3.0.CO;2-C","volume":"70","author":"DE Henson","year":"1992","unstructured":"Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498\u2013501.","journal-title":"Cancer."},{"issue":"6","key":"6610_CR39","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U","volume":"70","author":"DE Henson","year":"1992","unstructured":"Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1493\u20137.","journal-title":"Cancer."},{"issue":"6 Suppl 20","key":"6610_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sonc.2002.37371","volume":"29","author":"Y Nimura","year":"2002","unstructured":"Nimura Y. Extended surgery in bilio-pancreatic cancer: the Japanese experience. Semin Oncol. 2002;29(6 Suppl 20):17\u201322.","journal-title":"Semin Oncol"},{"issue":"8","key":"6610_CR41","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/cncr.10831","volume":"95","author":"T Takada","year":"2002","unstructured":"Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685\u201395.","journal-title":"Cancer."},{"issue":"2","key":"6610_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. Jama. 2012;308(2):147\u201356.","journal-title":"Jama."},{"key":"6610_CR43","doi-asserted-by":"crossref","unstructured":"Capecitabine extends survival for biliary tract cancer. Cancer Discov. 2017;7(7):Of1.","DOI":"10.1158\/2159-8290.CD-NB2017-079"},{"issue":"5","key":"6610_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol"},{"key":"6610_CR45","volume-title":"Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial","author":"J Edeline","year":"2017","unstructured":"Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly J-P, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trialAmerican Society of Clinical Oncology; 2017."},{"issue":"3","key":"6610_CR46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","volume":"242","author":"DJ Rea","year":"2005","unstructured":"Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451\u20138 discussion 8-61.","journal-title":"Ann Surg"},{"issue":"8","key":"6610_CR47","first-page":"873","volume":"20","author":"BG Czito","year":"2006","unstructured":"Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park). 2006;20(8):873\u201384 discussion 86\u20138, 93\u20135.","journal-title":"Oncology (Williston Park)"},{"key":"6610_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/1748-717X-8-292","volume":"8","author":"YI Kim","year":"2013","unstructured":"Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiation Oncol (London, England). 2013;8:292.","journal-title":"Radiation Oncol (London, England)"},{"issue":"1","key":"6610_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"issue":"12","key":"6610_CR50","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6610-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T14:40:43Z","timestamp":1613227243000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6610-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6610"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6610-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"3 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial protocol was approved by the responsible lead ethics committee of the Landes\u00e4rtzekammer Hessen, Hanauer Landstr. 152, 60314 Frankfurt am Main, Germany, responsible for the Krankenhaus Nordwest Frankfurt- UCT (University Cancer Center) on the 11th January 2019 under the identification number FF 108\/2019. An amendment of the study was approved by the responsible lead ethics committee on 26th July 2019, Version 1.4. The trial has been registered on the\n                      \n                      website under the identification number NCT03673072\n                      \n                      . The GAIN study complies with the Declaration of Helsinki rules, the principles of Good Clinical Practice guidelines and the Data Protection Act. The study will also be carried out in compliance to local legal and regulatory requirements. For each patient to be enrolled into the study, obtaining written informed consent prior to trial inclusion is essential.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}